| GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows: Conference call details: | Date: | February 26, 2026 | Time: | 8:30 a.m. ET | URL to register phone: | Register Here | Dial-in number: | (888) 880-3330 (U.S.) or |
| (+1) (646) 357-8766 (International) | Webcast: | ir.novavax.com/events |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: |
| Date: | Available starting at 11:30 a.m. ET, February 26, 2026, until 11:59 p.m. ET, March 5, 2026 | Dial-in number: | (800) 770-2030 (U.S.) or |
| (+1) (609) 800-9909 (International) | Passcode: | 9610065# | Webcast: | ir.novavax.com/events, until March 25, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information. Contacts: Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com Media
Yvonne Sprow
844-264-8571
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-302692051.html
SOURCE Novavax, Inc. | |
